Date: 2014-10-28
Type of information: Licensing agreement
Compound: PEI-based transfection technologies
Company: Polyplus-transfection (France) Blue Sky BioServices (USA - MA)
Therapeutic area: Technology - Services
Type agreement: R&D licensing commercialisation
Action mechanism:
Disease:
Details: * On October 28, 2014, Polyplus-transfection, a privately-held company developing innovative technologies for molecular and cellular biology, and Blue Sky BioServices, a contract research organization (CRO) providing Gene Through Screen services for the pharmaceutical and biotechnology R&D market, announced a non-exclusive, research and commercial license agreement. Polyplus has granted Blue Sky BioServices a licence to use Polyethylenimine (PEI) for in vitro transfection applications. Blue Sky BioServices, has become the 17th sub-licensee, and the 4th CRO to acquire rights from Polyplus to use its PEI-mediated transfection applications for research and commercial purposes. Of the other international Polyplus sub-licensees, five are big pharma companies. Six are in located in North America, and 11 in Europe. The license provides Blue Sky BioServices with freedom to use this globally recognized high performance technology from Polyplus-transfection to generate transfected cells to produce proteins, viruses and antibodies.
Financial terms: Financial terms were not disclosed.
Latest news:
